1,3-dinitronaphthalen-4-yl trifluoromethanesulfonate | 161393-72-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,3-dinitronaphthalen-4-yl trifluoromethanesulfonate
• 英文别名: 2,4-dinitronaphthalen-1-yl trifluoromethanesulfonate；2,4-dinitro-1-naphthyl trifluoromethanesulfonate；Trifluoromethanesulfonic acid-(2,4-dinitronaphth-1-ol)-ester；(2,4-dinitronaphthalen-1-yl) trifluoromethanesulfonate
• CAS: 161393-72-2
• 化学式: C₁₁H₅F₃N₂O₇S
• 分子量: 366.231
• InChiKey: ZVHGWZSTPKELFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  143
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  1,3-dinitronaphthalen-4-yl trifluoromethanesulfonate 在 sodium iodide 、 tin(ll) chloride 作用下， 以 乙酸乙酯 为溶剂， 反应 4.5h， 生成 1,3-萘二胺
  参考文献：
  名称：

  3-取代的5-氨基-1-（氯甲基）-1，2-二氢-3H-苯并[e]吲哚（氨基-CBI）的新短合成。

  摘要：

  公开了一种来自Martius Yellow的3-取代的5-取代的5-氨基-1-（氯甲基）-1，2-二氢-3H-苯并[e]吲哚的新的短合成物。合成的关键步骤是三个有效的区域选择性反应（碘化，5-exo-trig芳基自由基-烯烃环化和羧化）。

  DOI：

  10.1021/jo0263115
• 作为产物：
  描述：

  马休黄 在 trifluoromethanesulfonic acid anhydride 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 1,3-dinitronaphthalen-4-yl trifluoromethanesulfonate
  参考文献：
  名称：

  Benzo\x9bf!quinoxalinedione derivatives, their production and use in

  摘要：

  化合物的化学式I ##STR1## 描述了其中取代基R.sup.1 -R.sup.4的含义，以及它们在制药剂中的生产和用途。

  公开号：

  US05710138A1

文献信息

• Observation by NMR of cationic Wheland-like intermediates in the deiodination of protected 1-iodonaphthalene-2,4-diamines in acidic media
  作者：Elvis A. Twum、Timothy J. Woodman、Wenyi Wang、Michael D. Threadgill

  DOI：10.1039/c3ob41386a

  日期：——

  1-Iodonaphthalene-2,4-diamines in trifluoroacetic acid/chloroform give stable Wheland-like tetrahedral cationic species observable by NMR, through an initial intramolecular protonation. Dynamic equilibria allow proton-deuterium exchange of aromatic protons and provide a mechanism for deiodination of 1-iodonaphthalene-2,4-diamines.

  在三氟乙酸/氯仿中，1-碘萘-2,4-二胺通过最初的分子内质子化作用，产生了可通过核磁共振观测到的稳定的惠兰四面体阳离子物种。动态平衡允许芳香质子进行质子-氘交换，为 1-碘萘-2,4-二胺的脱碘反应提供了一种机制。
• [EN] PROCESSES FOR PREPARING 3-SUBSTITUTED 1-(CHLOROMETHYL)-1,2-DIHYDRO-3H-[RING FUSED INDOL-5-YL(AMINE-DERIVED)] COMPOUNDS AND ANALOGUES THEREOF, AND TO PRODUCTS OBTAINED THEREFROM<br/>[FR] PROCEDE DE PREPARATION DE COMPOSES DE 3-SUBSTITUE 1-(CHLOROMETHYL)-1,2-DIHYDRO-3H [-5-YL A CYCLES FUSIONNES (DERIVES D'AMINE)] ET DE LEURS ANALOGUES, ET PRODUITS DERIVES
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2003097635A1

  公开（公告）日：2003-11-27

  The invention provides processes of preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl(amine-derived)] compounds of formula (I) and its analogues, or a physiologically functional derivative thereof, (I), wherein A and B together may represent a fused optionally substituted benzene, naphthalene, pyridine, furan or a pyrrole ring, where the optional substituents are represented by Y; X is halogen or OSO2R , and W is selected from NO2, NHOH, N(R3)2NHR3, NHCO2R3, N(phthaloyl) or NH2, or W is further selected from the group (a) , wherein J is selected from OH or R, and P is a group which is a substrate suitable for a nitroreductase or carboxypeptidase enzyme. The invention is also directed to the use of compounds of formula (I) prepared by the processes of the invention as cytotoxins for cancer therapy and as prodrugs for gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT).

  该发明提供了制备公式（I）及其类似物的3-取代1-(氯甲基)-1,2-二氢-3H-[环融合吲哚-5-基（衍生自胺基）]化合物的过程，或其生理功能衍生物，其中A和B一起可以表示一个融合的可选取代苯、萘、吡啶、呋喃或吡咯环，其中可选取代基由Y表示；X为卤素或OSO2R，W从NO2、NHOH、N(R3)2NHR3、NHCO2R3、N(邻苯二甲酰基)或NH2中选择，或W进一步从群（a）中选择，其中J从OH或R中选择，P是适用于硝基还原酶或羧肽酶的底物基团。该发明还涉及通过该发明的过程制备的公式（I）化合物作为抗癌细胞毒素以及基因导向酶-前药疗法（GDEPT）和抗体导向酶-前药疗法（ADEPT）的前药的用途。
• Androgen receptor modulators and methods of treating disease using the same
  申请人：Schlienger Nathalie

  公开号：US20070004679A1

  公开（公告）日：2007-01-04

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文公开了一种公式（I）的双环芳基化合物，其选择性调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及包括向需要治疗的患者给予公式（I）化合物的治疗疾病的方法。
• Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom
  申请人：Denny Alexander William

  公开号：US20050148651A1

  公开（公告）日：2005-07-07

  The invention provides processes of preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl(amine-derived)] compounds of formula (I) and its analogues, or a physiologically functional derivative thereof, (I), wherein A and B together may represent a fused optionally substituted benezene, naphthalene, pyridine, furan or a pyrrole ring, where the optional substituents are represented by Y; X is halogen or OSO 2 R, and W is selected from NO 2 , NHOH, N(R 3 ) 2 NHR 3 , NHCO 2 R 3 , N(phthaloyl) or NH 2 , or W is further selected from the group (a), wherein J is selected from OH or R, and P is a group which is a substrate suitable for a nitroreductase or carboxypeptidase enzyme. The invention is also directed to the use of compounds of formula (I) prepared by the processes of the invention as cytotoxins for cancer therapy and as prodrugs for gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT).

  本发明提供了制备式(I)及其类似物或其生理功能衍生物的3-取代-1-(氯甲基)-1,2-二氢-3H-[环融合吲哚-5-基(氨基衍生)]化合物的过程，其中A和B在一起可以表示为融合的可选取代苯、萘、吡啶、呋喃或吡咯环，其中可选的取代基由Y表示；X是卤素或OSO2R，W从NO2、NHOH、N(R3)2NHR3、NHCO2R3、N(phthaloyl)或NH2中选择，或者W进一步从(a)组中选择，其中J从OH或R中选择，P是适用于硝基还原酶或羧肽酶酶的底物基团。本发明还涉及使用通过本发明的方法制备的式(I)化合物作为癌症治疗的细胞毒素以及基因导向酶前药治疗(GDEPT)和抗体导向酶前药治疗(ADEPT)的前药。
• Androgen receptor modulators and method of treating disease using the same
  申请人：Schlienger Nathalie

  公开号：US20060014739A1

  公开（公告）日：2006-01-19

  Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating disease comprising administering a compound of Formula (I) to a patient in need thereof.

  本文公开了式(I)的双环芳基化合物，其选择性调节核受体，优选为雄激素受体，或其药学上可接受的盐、酯、酰胺或前药，以及通过向需要治疗的患者施用式(I)化合物的方法治疗疾病。